Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dolutegravir/GSK 3640254 - ViiV Healthcare

Next Previous
Drug Profile

Dolutegravir/GSK 3640254 - ViiV Healthcare

Alternative Names: Dolutegravir/BMS 986197; Dolutegravir/GSK-254; Dolutegravir/GSK-3640254; DTG/GSK3640254; GSK-3640254/Dolutegravir; GSK3640254/DTG

Latest Information Update: 28 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ViiV Healthcare
  • Class 3-ring heterocyclic compounds; Amides; Antiretrovirals; Oxazines; Small molecules
  • Mechanism of Action Capsid protein inhibitors; HIV integrase inhibitors; HIV replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 28 May 2024 No recent reports of development identified for phase-I development in HIV-infections(In volunteers) in USA (PO, Tablet)
  • 10 Sep 2021 ViiV Healthcare completes a phase I clinical trial in HIV infections (In volunteers) in USA (PO) (NCT04857892)
  • 23 Apr 2021 Preclinical trials in HIV infections in USA (PO) prior to April 2021

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top